The Legend Capital-backed sacral neuromodulation device developer floated in the middle of its range while upping the number of shares in the IPO.

Novartis and Access Industries were among the investors that bought $37.5m of the shares, which the cell therapy developer issued at a downgraded price.

Sina invested $5m as online financing platform Pintec, which also counts Xiaomi as an investor, went public in a $44.3m initial public offering.

The Brazilian payment and commerce services provider floated above its range and raised an extra $100m from Ant Financial through a private placement.

Legend Holdings, Eli Lilly, Ping An, China Life and Taikang-backed Innovent Biologics priced its shares near the top of the range of to raise $421m.

Orphan disease drug developer PhaseBio Pharmaceuticals, which is commercialising research from Duke University, cut the price of its shares sharply pre-offering.

Orphan disease drug developer PhaseBio Pharmaceuticals, which counts Johnson & Johnson, Astellas and AstraZeneca as investors, cut the price of its shares sharply pre-offering.

The Novo-backed surgical implant provider floated at the top of its range and increased the number of shares in the offering.

Existing investor Biocon bought more shares in a $65.4m offering that involved the immuno-inflammatory disorder drug developer floating at the bottom of its range.

The underwriters took up the option to buy another 2.7 million shares after the Pfizer and Gilead-backed oncology therapy developer's shares leapt substantially post-IPO.